Acetylcholinesterase Inhibitors as Potential Anti-Alzheimer Drugs: Prooxidative and Cytogenotoxic Properties (SafeAChE)
Project code: 337-00-205/2019-09/19
Project type: Project of bilateral scientific and technological cooperation between Republic of Croatia and Republic of Serbia
Project funding: Serbian Ministry of Education, Science, and Technological Development; Croatian Ministry of Science and Education
Project duration: 1st May, 2019 – 30th April, 2021
Serbian team: Mirjana Čolović, PhD (COST member); Danijela Krstić, PhD (COST member); Marko Dinčić, PhD student; Branislava Savić, PhD student;
Croatian team: Goran Gajski, PhD (COST member); Marko Gerić, PhD; Mirta Milić, PhD; Ana-Marija Domijan, PhD;
Acetylcholinesterase (AChE) is a serine hydrolase that terminates impulse transmission at cholinergic synapses by the rapid hydrolysis of neurotransmitter acetylcholine. Reversible inhibitors of this enzyme have been applied in the symptomatic treatment of Alzheimer’s disease associated with the loss of cholinergic neurons in the brain and the decreased level of acetylcholine.
Although the AChE inhibitor therapy results in improving cognitive abilities, the long-term application may induce undesirable side effects such as gastrointestinal problems and hepatotoxicity. For this reason, new compounds have been synthesized in order to find both efficient and less toxic pharmaceuticals for neurological disorders. Considering toxicity is a main limitation in the clinical application of physiologically active agents, the objective of this project is to evaluate in vitro prooxidative and genotoxic effects of synthesized metal-based compounds, promising anti-Alzheimer therapeutics exhibiting strong anti-AChE action.
(Posted on 10 September 2019)